Should adjuvant CRT be considered in gastric cancer patients who received pre-op chemo based on the recent results of the CRITICS trial?
The CRITICS trial showed there was no OS or PFS benefit with adj chemo vs CRT. Is there potentially still a role for CRT to reduce heme toxicity and potentially improve LRC?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on
There are many nuances here, but CRITICS suggests that there is little if any benefit to the routine use of postoperative chemoRT, in addition to pre- and post-op chemo, in resected gastric cancer patients who undergo a D2 dissection. The only scenario where I really consider postop CRT to be strong...
Join for free or sign in to see the full answer